Organization
Janssen R&D, LLC, Spring House, United States
4 abstracts
Abstract
5 YEAR SAFETY, EFFICACY, AND RADIOGRAPHIC DATA IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH GOLIMUMAB: LONG-TERM EXTENSION RESULTS OF THE RANDOMIZED, PLACEBO-CONTROLLED STUDY GO-REVEAL Org: Janssen R&D, LLC, Spring House, United States,
Abstract
ANTIBODIES TO ETANERCEPT AND ADALIMUMAB IN RHEUMATOID ARTHRITIS INADEQUATE RESPONDERS AND CLINICAL OUTCOMES AFTER AN ACTIVE SWITCH TO INFLIXIMAB Org: Janssen Services, LLC, Horsham, Janssen R&D, LLC, Spring House, United States, Helsinki U Central Hosp, Helsinki, Finland, Rheumatology, Atlanta, Metroplex Clinical Res Ctr, Dallas, United States,
Abstract
A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF SUBCUTANEOUSLY ADMINISTERED USTEKINUMAB AND GUSELKUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE TREATMENT WITH METHOTREXATE Org: Janssen R&D, LLC, Spring House, United States, Janssen R&D, LLC, La Jolla, Janssen Scientific Affairs, LLC, Horsham, PA, Baylor College of Medicine,
Abstract
A COMPARISON OF EQ5D INDEX FROM THE UK, US, AND JAPAN PREFERENCE WEIGHTS MODEL, AND MAPPING ALGORITHM FROM CLINICAL OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS OF FROM SIMPONI ARIA STUDY Org: J&J Pharmaceutical Services, LLC., Malvern, Johns Hopkins University, Baltimore, United States, UZ Gasthuisberg, Leuven, Belgium, Brigham & Women's Hospital, Boston, Janssen R&D, LLC, Spring House, United States,